Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta
Prostate cancer (PC) is the most common urogenital malignancy in older men and the second leading cause of death by cancer in men in Europe. Current therapeutic practice considers Androgen Deprivation Therapy (ADT) as first line treatment for clinically localized prostate cancer at high-risk, either...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2017-07-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/10742.pdf |